Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
Blenrep (belantamab mafodotin) in combination receives Breakthrough Therapy Designation in China for treatment of relapsed/refractory multiple myeloma
Granted based on results from phase III head-to-head DREAMM-7 trial.
Download (PDF, 136.8KB) -
GSK announces positive headline data from phase II seasonal influenza mRNA vaccine programme
Data support progression to phase III clinical trials.
Download (PDF, 128.7KB) -
GSK provides update on phase I/II therapeutic herpes simplex virus (HSV) vaccine trial
Results show that GSK3943104 did not meet the study’s primary efficacy objective.
Download (PDF, 121.3KB) -
Statement: Zantac (ranitidine) litigation – Dixon case
GSK confirmed it has reached a settlement with Mr. Isaac Dixon, resolving the prostate cancer case filed in Illinois State Court.
Download (PDF, 112.0KB) -
Depemokimab late-breaking data presented at ERS show a 54% reduction in severe asthma exacerbations
SWIFT-1 and SWIFT-2 phase III data show depemokimab delivered statistically significant and clinically meaningful reduction in exacerbations
Download (PDF, 185.7KB) -
GSK announces positive results from phase III trial of Nucala (mepolizumab) in COPD
GSK announces positive headline results of MATINEE, the phase III clinical trial evaluating Nucala (mepolizumab) in adults with COPD.
Download (PDF, 170.6KB) -
GSK aims to redefine the future of respiratory medicine at the European Respiratory Society International Congress
Presenting 56 abstracts to advance scientific understanding and support ambition to improve the lives of people with respiratory conditions
Download (PDF, 168.7KB) -
European Commission approves expanded age indication for GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk
Authorisation helps protect this population for the first time ahead of this RSV season
Download (PDF, 391.3KB) -
GSK’s Nucala (mepolizumab) approved in Japan for treatment of adults with chronic rhinosinusitis with nasal polyps
Nucala is the first and only biologic in Japan with a four-weekly dosing schedule for this condition
Download (PDF, 255.2KB) -
Bepirovirsen granted SENKU designation in Japan for chronic hepatitis B
Designation expedites review of bepirovirsen as a potential treatment for people living with chronic hepatitis B (CHB)
Download (PDF, 188.9KB) -
Statement: Zantac (ranitidine) litigation – Delaware Supreme Court to review Superior Court’s Daubert decision
Zantac (ranitidine) litigation – Delaware Supreme Court to review Superior Court’s Daubert decision
Download (PDF, 123.0KB) -
GSK receives US FDA Breakthrough Therapy Designation for its B7-H3-targeted antibody-drug conjugate in relapsed or refractory extensive-stage small-cell lung cancer
Regulatory designation based on promising early clinical evidence observed with GSK5764227 in this tumour type
Download (PDF, 141.5KB) -
Statement: Zantac (ranitidine) litigation – Florida State Court Daubert Ruling in Wilson case
Zantac (ranitidine) litigation – Florida State Court Daubert Ruling in Wilson case
Download (PDF, 124.1KB) -
Statement: Zantac (ranitidine) litigation – Joiner case
Jury in Joiner case in Illinois state court finds GSK not liable for plaintiff’s colorectal cancer
Download (PDF, 126.9KB) -
US FDA expands Jemperli (dostarlimab) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
Jemperli approval now includes MMRp/MSS tumours, which represent majority of endometrial cancer cases.
Download (PDF, 181.9KB) -
GSK delivers continued strong performance and upgrades 2024 guidance
Q2 2024 performance highlights
Download (PDF, 1.1MB) -
GSK presents new data at the Alzheimer's Association International Conference 2024
ZOSTER-122 retrospective study presented during Featured Research Session on shingles and dementia risk
Download (PDF, 230.9KB) -
Arexvy, GSK’s Respiratory Syncytial Virus (RSV) vaccine, receives positive European Medicines Agency CHMP opinion for adults aged 50-59 at increased risk for RSV disease
If approved, this will be the first vaccine in the EU for adults aged 50-59 who are at increased risk of RSV disease.
Download (PDF, 432.6KB) -
Statement: Zantac (ranitidine) litigation – Kimbrow case
GSK has reached a confidential settlement with Ronald Kimbrow resolving the case he filed in Illinois state court.
Download (PDF, 110.4KB) -
GSK and Flagship Pioneering partner to discover novel medicines and vaccines
Collaboration brings together GSK disease area expertise and development capability with Flagship portfolio of 40+ bioplatform companies
Download (PDF, 130.7KB)
